{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:48:46Z","timestamp":1783529326298,"version":"3.55.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s00281-014-0424-x","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T17:35:52Z","timestamp":1400175352000},"page":"339-350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["B cells in MS and NMO: pathogenesis and therapy"],"prefix":"10.1007","volume":"36","author":[{"given":"Markus","family":"Krumbholz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Meinl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,16]]},"reference":[{"key":"424_CR1","unstructured":"Hauser S, Waubant E, Arnold D, Vollmer T, Antel J, et al. (2007). A phase II randomized, placebo-controlled, multicenter trial of rituximab in adults with relapsing remitting multiple sclerosis (RRMS) Neurology 68 (12): Suppl. 1: A99-A100"},{"key":"424_CR2","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","volume":"76","author":"HL Pellkofer","year":"2011","unstructured":"Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA et al (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76:1310\u20131315","journal-title":"Neurology"},{"key":"424_CR3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1742-2094-9-80","volume":"9","author":"M Koziolek","year":"2012","unstructured":"Koziolek M, Tampe D, Bahr M, Dihazi H, Jung K et al (2012) Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis. J Neuroinflammation 9:80\u201389","journal-title":"J Neuroinflammation"},{"key":"424_CR4","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(05)67102-4","volume":"366","author":"M Keegan","year":"2005","unstructured":"Keegan M, Konig F, McClelland R, Bruck W, Morales Y et al (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366:579\u2013582","journal-title":"Lancet"},{"key":"424_CR5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.atherosclerosissup.2012.10.025","volume":"14","author":"F Heigl","year":"2013","unstructured":"Heigl F, Hettich R, Arendt R, Durner J, Koehler J et al (2013) Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients. Atheroscler Suppl 14:167\u2013173","journal-title":"Atheroscler Suppl"},{"key":"424_CR6","author":"C Trebst","year":"2013","unstructured":"Trebst C, Jarius S, Berthele A, Paul F, Schippling S et al (2013) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. doi: 10.1007\/s00415-013-7169-7","journal-title":"J Neurol"},{"key":"424_CR7","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/aws105","volume":"135","author":"C Elliott","year":"2012","unstructured":"Elliott C, Lindner M, Arthur A, Brennan K, Jarius S et al (2012) Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain 135:1819\u20131833","journal-title":"Brain"},{"key":"424_CR8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jneuroim.2012.02.015","volume":"246","author":"RP Lisak","year":"2012","unstructured":"Lisak RP, Benjamins JA, Nedelkoska L, Barger JL, Ragheb S et al (2012) Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro. J Neuroimmunol 246:85\u201395","journal-title":"J Neuroimmunol"},{"key":"424_CR9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473\u2013477","journal-title":"J Exp Med"},{"key":"424_CR10","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","volume":"66","author":"M Bradl","year":"2009","unstructured":"Bradl M, Misu T, Takahashi T, Watanabe M, Mader S et al (2009) Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66:630\u2013643","journal-title":"Ann Neurol"},{"key":"424_CR11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","volume":"66","author":"JL Bennett","year":"2009","unstructured":"Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K et al (2009) Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66:617\u2013629","journal-title":"Ann Neurol"},{"key":"424_CR12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jneuroim.2012.09.010","volume":"254","author":"N Asgari","year":"2013","unstructured":"Asgari N, Khorooshi R, Lillevang ST, Owens T (2013) Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid. J Neuroimmunol 254:76\u201382","journal-title":"J Neuroimmunol"},{"key":"424_CR13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2051-5960-1-5","volume":"1","author":"M Kitic","year":"2013","unstructured":"Kitic M, Hochmeister S, Wimmer I, Bauer J, Misu T et al (2013) Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats. Acta Neuropathol Commun 1:5","journal-title":"Acta Neuropathol Commun"},{"key":"424_CR14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","volume":"47","author":"C Lucchinetti","year":"2000","unstructured":"Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M et al (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707\u2013717","journal-title":"Ann Neurol"},{"key":"424_CR15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ana.21311","volume":"63","author":"ECW Breij","year":"2008","unstructured":"Breij ECW, Brink BP, Veerhuis R, van den Berg C, Vloet R et al (2008) Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 63:16\u201325","journal-title":"Ann Neurol"},{"key":"424_CR16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ana.21524","volume":"65","author":"MH Barnett","year":"2009","unstructured":"Barnett MH, Parratt JD, Cho ES, Prineas JW (2009) Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 65:32\u201346","journal-title":"Ann Neurol"},{"key":"424_CR17","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G et al (2002) A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain 125:1450\u20131461","journal-title":"Brain"},{"key":"424_CR18","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00401-013-1116-7","volume":"125","author":"T Misu","year":"2013","unstructured":"Misu T, Hoftberger R, Fujihara K, Wimmer I, Takai Y et al (2013) Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol 125:815\u2013827","journal-title":"Acta Neuropathol"},{"key":"424_CR19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/314537a0","volume":"314","author":"A Lanzavecchia","year":"1985","unstructured":"Lanzavecchia A (1985) Antigen-specific interaction between T and B cells. Nature 314:537\u2013539","journal-title":"Nature"},{"key":"424_CR20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nri2454","volume":"9","author":"FD Batista","year":"2009","unstructured":"Batista FD, Harwood NE (2009) The who, how and where of antigen presentation to B cells. Nat Rev Immunol 9:15\u201327","journal-title":"Nat Rev Immunol"},{"key":"424_CR21","author":"N Molnarfi","year":"2013","unstructured":"Molnarfi N, Schulze-Topphoff U, Weber MS, Patarroyo JC, Prod\u2019homme T et al (2013) MHC class II\u2013dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med. doi: 10.1084\/jem.20130699","journal-title":"J Exp Med"},{"key":"424_CR22","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/ni1542","volume":"9","author":"G Cinamon","year":"2008","unstructured":"Cinamon G, Zachariah MA, Lam OM, Foss FW Jr, Cyster JG (2008) Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat Immunol 9:54\u201362","journal-title":"Nat Immunol"},{"key":"424_CR23","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.4049\/jimmunol.169.10.5415","volume":"169","author":"AF Vos de","year":"2002","unstructured":"de Vos AF, van Meurs M, Brok HP, Boven LA, Hintzen RQ et al (2002) Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J Immunol 169:5415\u20135423","journal-title":"J Immunol"},{"key":"424_CR24","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1172\/JCI63842","volume":"122","author":"HC Budingen von","year":"2012","unstructured":"von Budingen HC, Kuo TC, Sirota M, van Belle CJ, Apeltsin L et al (2012) B cell exchange across the blood\u2013brain barrier in multiple sclerosis. J Clin Invest 122:4533\u20134543","journal-title":"J Clin Invest"},{"key":"424_CR25","doi-asserted-by":"crossref","unstructured":"Mayer MC, Hohlfeld R, Meinl E Viability of autoantibody-targets: how to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis. J Neurol Sci. doi: 10.1016\/j.jns.2012.05.018","DOI":"10.1016\/j.jns.2012.05.018"},{"key":"424_CR26","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/ana.20890","volume":"59","author":"E Meinl","year":"2006","unstructured":"Meinl E, Krumbholz M, Hohlfeld R (2006) B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 59:880\u2013892","journal-title":"Ann Neurol"},{"key":"424_CR27","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20111675","volume":"209","author":"TA Barr","year":"2012","unstructured":"Barr TA, Shen P, Brown S, Lampropoulou V, Roch T et al (2012) B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6 producing B cells. J Exp Med 209:1001\u20131010","journal-title":"J Exp Med"},{"key":"424_CR28","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/08916934.2012.665529","volume":"45","author":"SJ Ireland","year":"2012","unstructured":"Ireland SJ, Blazek M, Harp CT, Greenberg B, Frohman EM et al (2012) Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity. Autoimmunity 45:400\u2013414","journal-title":"Autoimmunity"},{"key":"424_CR29","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/ni833","volume":"3","author":"S Fillatreau","year":"2002","unstructured":"Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3:944\u2013950","journal-title":"Nat Immunol"},{"issue":"7492","key":"424_CR30","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nature12979","volume":"507","author":"P Shen","year":"2014","unstructured":"Shen P, Roch T, Lampropoulou V, O\u2019Connor RA, Hilgenberg E et al (2014) IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507(7492):366\u201370","journal-title":"Nature"},{"key":"424_CR31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2012.02.008","volume":"36","author":"A Bosma","year":"2012","unstructured":"Bosma A, Abdel-Gadir A, Isenberg David A, Jury Elizabeth C, Mauri C (2012) Lipid-antigen presentation by CD1d\u2009+\u2009B cells is essential for the maintenance of invariant natural killer T cells. Immunity 36:477\u2013490","journal-title":"Immunity"},{"key":"424_CR32","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1172\/JCI200423594","volume":"114","author":"DI Godfrey","year":"2004","unstructured":"Godfrey DI, Kronenberg M (2004) Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 114:1379\u20131388","journal-title":"J Clin Invest"},{"key":"424_CR33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nature11501","volume":"491","author":"A Yoshizaki","year":"2012","unstructured":"Yoshizaki A, Miyagaki T, DiLillo DJ, Matsushita T, Horikawa M et al (2012) Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 491:264\u2013268","journal-title":"Nature"},{"key":"424_CR34","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.4049\/jimmunol.161.7.3299","volume":"161","author":"E Bettelli","year":"1998","unstructured":"Bettelli E, Das MP, Howard ED, Weiner HL, Sobel RA et al (1998) IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J Immunol 161:3299\u20133306","journal-title":"J Immunol"},{"key":"424_CR35","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4049\/jimmunol.0900296","volume":"184","author":"SJ Cohen","year":"2010","unstructured":"Cohen SJ, Cohen IR, Nussbaum G (2010) IL-10 mediates resistance to adoptive transfer experimental autoimmune encephalomyelitis in MyD88(\u2212\/\u2212) mice. J Immunol 184:212\u2013221","journal-title":"J Immunol"},{"key":"424_CR36","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.autrev.2011.11.018","volume":"11","author":"A Kessel","year":"2012","unstructured":"Kessel A, Haj T, Peri R, Snir A, Melamed D et al (2012) Human CD19\u2009+\u2009CD25high B regulatory cells suppress proliferation of CD4+ T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun Rev 11:670\u2013677","journal-title":"Autoimmun Rev"},{"key":"424_CR37","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrrheum.2010.140","volume":"6","author":"C Mauri","year":"2010","unstructured":"Mauri C, Blair PA (2010) Regulatory B cells in autoimmunity: developments and controversies. Nat Rev Rheumatol 6:636\u2013643","journal-title":"Nat Rev Rheumatol"},{"key":"424_CR38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jneuroim.2011.08.019","volume":"239","author":"S Knippenberg","year":"2011","unstructured":"Knippenberg S, Peelen E, Smolders J, Thewissen M, Menheere P et al (2011) Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced na\u00efve\/memory Breg ratio during a relapse but not in remission. J Neuroimmunol 239:80\u201386","journal-title":"J Neuroimmunol"},{"key":"424_CR39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1352458512454771","volume":"19","author":"C Quan","year":"2013","unstructured":"Quan C, Yu H, Qiao J, Xiao B, Zhao G et al (2013) Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis. Mult Scler J 19:289\u2013298","journal-title":"Mult Scler J"},{"key":"424_CR40","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jocn.2011.01.031","volume":"18","author":"HH Wang","year":"2011","unstructured":"Wang HH, Dai YQ, Qiu W, Lu ZQ, Peng FH et al (2011) Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci 18:1313\u20131317","journal-title":"J Clin Neurosci"},{"key":"424_CR41","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1017\/S0317167100015663","volume":"39","author":"A Wu","year":"2012","unstructured":"Wu A, Zhong X, Wang H, Xu W, Cheng C et al (2012) Cerebrospinal fluid IL-21 levels in neuromyelitis optica and multiple sclerosis. Can J Neurol Sci 39:813\u2013820","journal-title":"Can J Neurol Sci"},{"key":"424_CR42","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.4049\/jimmunol.1201678","volume":"190","author":"BB Ding","year":"2013","unstructured":"Ding BB, Bi E, Chen H, Yu JJ, Ye BH (2013) IL-21 and CD40L synergistically promote plasma cell differentiation through upregulation of Blimp-1 in human B cells. J Immunol 190:1827\u20131836","journal-title":"J Immunol"},{"key":"424_CR43","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature05970","volume":"448","author":"T Korn","year":"2007","unstructured":"Korn T, Bettelli E, Gao W, Awasthi A, Jager A et al (2007) IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature 448:484\u2013487","journal-title":"Nature"},{"key":"424_CR44","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","volume":"13","author":"I Schwab","year":"2013","unstructured":"Schwab I, Nimmerjahn F (2013) Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 13:176\u2013189","journal-title":"Nat Rev Immunol"},{"key":"424_CR45","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.1086907","volume":"301","author":"H Wardemann","year":"2003","unstructured":"Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E et al (2003) Predominant autoantibody production by early human B cell precursors. Science 301:1374\u20131377","journal-title":"Science"},{"key":"424_CR46","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.coi.2008.09.001","volume":"20","author":"E Meffre","year":"2008","unstructured":"Meffre E, Wardemann H (2008) B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 20:632\u2013638","journal-title":"Curr Opin Immunol"},{"key":"424_CR47","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1172\/JCI68775","volume":"123","author":"T Kinnunen","year":"2013","unstructured":"Kinnunen T, Chamberlain N, Morbach H, Cantaert T, Lynch M et al (2013) Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest 123:2737\u20132741","journal-title":"J Clin Invest"},{"key":"424_CR48","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ana.21939","volume":"67","author":"A Bar-Or","year":"2010","unstructured":"Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A et al (2010) Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 67:452\u2013461","journal-title":"Ann Neurol"},{"key":"424_CR49","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jneuroim.2008.04.031","volume":"199","author":"JL Bennett","year":"2008","unstructured":"Bennett JL, Haubold K, Ritchie AM, Edwards SJ, Burgoon M et al (2008) CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome. J Neuroimmunol 199:126\u2013132","journal-title":"J Neuroimmunol"},{"key":"424_CR50","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/gene.2013.18","volume":"14","author":"AJ Ligocki","year":"2013","unstructured":"Ligocki AJ, Rounds WH, Cameron EM, Harp CT, Frohman EM et al (2013) Expansion of CD27(high) plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation. Genes and Immunity 14:291\u2013301","journal-title":"Genes and Immunity"},{"key":"424_CR51","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrneurol.2012.203","volume":"8","author":"M Krumbholz","year":"2012","unstructured":"Krumbholz M, Derfuss T, Hohlfeld R, Meinl E (2012) B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol 8:613\u2013623","journal-title":"Nat Rev Neurol"},{"key":"424_CR52","first-page":"247","volume":"20","author":"T Hayashi","year":"2007","unstructured":"Hayashi T, Matsumoto I, Yasukochi T, Mamura M, Goto D et al (2007) Biased usage of synovial immunoglobulin heavy chain variable region 4 by the anti-glucose-6-phosphate isomerase antibody in patients with rheumatoid arthritis. Int J Mol Med 20:247\u2013253","journal-title":"Int J Mol Med"},{"key":"424_CR53","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1046\/j.1365-2249.1998.00580.x","volume":"112","author":"SC Huang","year":"1998","unstructured":"Huang SC, Jiang R, Hufnagle WO, Furst DE, Wilske KR et al (1998) VH usage and somatic hypermutation in peripheral blood B cells of patients with rheumatoid arthritis (RA). Clin Exp Immunol 112:516\u2013527","journal-title":"Clin Exp Immunol"},{"key":"424_CR54","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.4049\/jimmunol.163.2.1027","volume":"163","author":"T Dorner","year":"1999","unstructured":"Dorner T, Farner NL, Lipsky PE (1999) Ig lambda and heavy chain gene usage in early untreated systemic lupus erythematosus suggests intensive B cell stimulation. J Immunol 163:1027\u20131036","journal-title":"J Immunol"},{"key":"424_CR55","doi-asserted-by":"crossref","first-page":"R114","DOI":"10.1186\/ar627","volume":"5","author":"NL Fraser","year":"2003","unstructured":"Fraser NL, Rowley G, Field M, Stott DI (2003) The VH gene repertoire of splenic B cells and somatic hypermutation in systemic lupus erythematosus. Arthritis Res Ther 5:R114\u2013R121","journal-title":"Arthritis Res Ther"},{"key":"424_CR56","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2009.05.014","volume":"213","author":"EM Cameron","year":"2009","unstructured":"Cameron EM, Spencer S, Lazarini J, Harp CT, Ward ES et al (2009) Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis. J Neuroimmunol 213:123\u2013130","journal-title":"J Neuroimmunol"},{"key":"424_CR57","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jneuroim.2010.06.016","volume":"226","author":"AJ Ligocki","year":"2010","unstructured":"Ligocki AJ, Lovato L, Xiang D, Guidry P, Scheuermann RH et al (2010) A unique antibody gene signature is prevalent in the central nervous system of patients with multiple sclerosis. J Neuroimmunol 226:192\u2013193","journal-title":"J Neuroimmunol"},{"key":"424_CR58","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/WCO.0b013e3283533a64","volume":"25","author":"T Derfuss","year":"2012","unstructured":"Derfuss T, Meinl E (2012) Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment? Curr Opin Neurol 25:231\u2013238","journal-title":"Curr Opin Neurol"},{"key":"424_CR59","unstructured":"Brickshawana A, Hinson SR, Fryer JP, McKeon A, Pittock SJ, et al. (2013). KIR4.1-Specific IgG Not Detected in Multiple Sclerosis Patients\u2019 Sera (S506). Presented at Annual Meeting of the American Neurological Association, New Orleans, Louisiana, USA"},{"key":"424_CR60","author":"L Querol","year":"2013","unstructured":"Querol L, Clark PL, Bailey MA, Cotsapas C, Cross AH et al (2013) Protein array-based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis. Neurology. doi: 10.1212\/WNL.0b013e3182a43b48","journal-title":"Neurology"},{"key":"424_CR61","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","volume":"9","author":"M Reindl","year":"2013","unstructured":"Reindl M, Di Pauli F, Rostasy K, Berger T (2013) The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 9:455\u2013461","journal-title":"Nat Rev Neurol"},{"key":"424_CR62","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","volume":"13","author":"KC O\u2019Connor","year":"2007","unstructured":"O\u2019Connor KC, McLaughlin KA, De Jager PL, Chitnis T, Bettelli E et al (2007) Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13:211\u2013217","journal-title":"Nat Med"},{"key":"424_CR63","doi-asserted-by":"crossref","unstructured":"Rostasy K, Mader S, Schanda K, Huppke P, Gartner J, et al. (2012). Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol","DOI":"10.1001\/archneurol.2011.2956"},{"key":"424_CR64","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","volume":"77","author":"AK Pr\u00f6bstel","year":"2011","unstructured":"Pr\u00f6bstel AK, Dornmair K, Bittner R, Sperl P, Jenne D et al (2011) Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 77:580\u2013588","journal-title":"Neurology"},{"key":"424_CR65","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.4049\/jimmunol.1301296","volume":"191","author":"MC Mayer","year":"2013","unstructured":"Mayer MC, Breithaupt C, Reindl M, Schanda K, Rostasy K et al (2013) Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol 191:3594\u20133604","journal-title":"J Immunol"},{"key":"424_CR66","author":"Y Hacohen","year":"2013","unstructured":"Hacohen Y, Absoud M, Woodhall M, Cummins C, De Goede CG et al (2013) Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort. J Neurol Neurosurg Psychiatry. doi: 10.1136\/jnnp-2013-306411","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"424_CR67","unstructured":"Titulaer MJ, Hoftberger R, Iizuka T, Rosenfeld MR, Graus F, et al. (2013). Overlap of Anti-NMDAR Encephalitis with Demyelinating Disorders (S528WIP). Presented at Annual Meeting of the American Neurological Association, New Orleans, Louisiana, USA"},{"key":"424_CR68","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-012-0986-4","volume":"123","author":"J Ratelade","year":"2012","unstructured":"Ratelade J, Zhang H, Saadoun S, Bennett JL, Papadopoulos MC et al (2012) Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol (Berl) 123:861\u2013872","journal-title":"Acta Neuropathol (Berl)"},{"key":"424_CR69","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","volume":"79","author":"J Kitley","year":"2012","unstructured":"Kitley J, Woodhall M, Waters P, Leite MI, Devenney E et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79:1273\u20131277","journal-title":"Neurology"},{"key":"424_CR70","doi-asserted-by":"crossref","unstructured":"Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, et al. (2011). Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 8:184.: 184","DOI":"10.1186\/1742-2094-8-184"},{"key":"424_CR71","unstructured":"Waters P, Woodhall M, Hacohen Y, O\u2019Connor K, Absoud M, et al. (2013). Antibodies to myelin oligodendrocyte glycoprotein (MOG) in children and adults with demyelinating disorders (NMO) (S503). Presented at Annual Meeting of the American Neurological Association, New Orleans, Louisiana, USA"},{"key":"424_CR72","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jns.2013.08.034","volume":"335","author":"M Woodhall","year":"2013","unstructured":"Woodhall M, Coban A, Waters P, Ekizoglu E, Kurtuncu M et al (2013) Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica. J Neurol Sci 335:221\u2013223","journal-title":"J Neurol Sci"},{"key":"424_CR73","doi-asserted-by":"crossref","first-page":"e74773","DOI":"10.1371\/journal.pone.0074773","volume":"8","author":"JS Tzartos","year":"2013","unstructured":"Tzartos JS, Stergiou C, Kilidireas K, Zisimopoulou P, Thomaidis T et al (2013) Anti-Aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders. PLoS One 8:e74773","journal-title":"PLoS One"},{"key":"424_CR74","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1177\/1352458512463483","volume":"19","author":"A Harrer","year":"2013","unstructured":"Harrer A, Tumani H, Niendorf S, Lauda F, Geis C et al (2013) Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler J 19:1209\u20131212","journal-title":"Mult Scler J"},{"key":"424_CR75","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/01.wnl.0000327671.91357.96","volume":"71","author":"M Krumbholz","year":"2008","unstructured":"Krumbholz M, Meinl I, K\u00fcmpfel T, Hohlfeld R, Meinl E (2008) Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 71:1350\u20131354","journal-title":"Neurology"},{"key":"424_CR76","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrneurol.2013.41","volume":"9","author":"M Stangel","year":"2013","unstructured":"Stangel M, Fredrikson S, Meinl E, Petzold A, Stuve O et al (2013) The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol 9:267\u2013276","journal-title":"Nat Rev Neurol"},{"key":"424_CR77","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.20041674","volume":"201","author":"M Krumbholz","year":"2005","unstructured":"Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F et al (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201:195\u2013200","journal-title":"J Exp Med"},{"key":"424_CR78","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1742-2094-9-93","volume":"9","author":"M Kowarik","year":"2012","unstructured":"Kowarik M, Cepok S, Sellner J, Grummel V, Weber M et al (2012) CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation 9:93","journal-title":"J Neuroinflammation"},{"key":"424_CR79","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/brain\/awh680","volume":"129","author":"M Krumbholz","year":"2006","unstructured":"Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisakk P et al (2006) Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 129:200\u2013211","journal-title":"Brain"},{"key":"424_CR80","doi-asserted-by":"crossref","first-page":"e11986","DOI":"10.1371\/journal.pone.0011986","volume":"5","author":"J Brettschneider","year":"2010","unstructured":"Brettschneider J, Czerwoniak A, Senel M, Fang L, Kassubek J et al (2010) The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One 5:e11986","journal-title":"PLoS One"},{"key":"424_CR81","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","volume":"14","author":"B Serafini","year":"2004","unstructured":"Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14:164\u2013174","journal-title":"Brain Pathol"},{"key":"424_CR82","doi-asserted-by":"crossref","first-page":"e70924","DOI":"10.1371\/journal.pone.0070924","volume":"8","author":"S Tada","year":"2013","unstructured":"Tada S, Yasui T, Nakatsuji Y, Okuno T, Koda T et al (2013) BAFF controls neural cell survival through BAFF receptor. PLoS One 8:e70924","journal-title":"PLoS One"},{"key":"424_CR83","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1523\/JNEUROSCI.5040-08.2009","volume":"29","author":"L Zhang","year":"2009","unstructured":"Zhang L, Zheng S, Wu H, Wu Y, Liu S et al (2009) Identification of BLyS (B lymphocyte stimulator), a non-myelin-associated protein, as a functional ligand for Nogo-66 receptor. J Neurosci 29:6348\u20136352","journal-title":"J Neurosci"},{"key":"424_CR84","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.pneurobio.2007.11.003","volume":"84","author":"M Li","year":"2008","unstructured":"Li M, Ransohoff RM (2008) Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol 84:116\u2013131","journal-title":"Prog Neurobiol"},{"key":"424_CR85","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.23651","volume":"72","author":"M Varrin-Doyer","year":"2012","unstructured":"Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM et al (2012) Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 72:53\u201364","journal-title":"Ann Neurol"},{"key":"424_CR86","doi-asserted-by":"crossref","unstructured":"Berer K, Mues M, Koutrolos M, Rasbi ZA, Boziki M, et al. (2011). Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature advance online publication: 538\u201341","DOI":"10.1038\/nature10554"},{"key":"424_CR87","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","volume":"378","author":"L Kappos","year":"2011","unstructured":"Kappos L, Li D, Calabresi PA, O\u2019Connor P, Bar-Or A et al (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378:1779\u20131787","journal-title":"Lancet"},{"key":"424_CR88","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:1819\u20131828","journal-title":"Lancet"},{"key":"424_CR89","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829\u20131839","journal-title":"Lancet"},{"key":"424_CR90","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1756285610371146","volume":"3","author":"HP Hartung","year":"2010","unstructured":"Hartung HP, Kieseier BC (2010) Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord 3:205\u2013216","journal-title":"Ther Adv Neurol Disord"},{"key":"424_CR91","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1074-7613(04)00079-2","volume":"20","author":"R Lesley","year":"2004","unstructured":"Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR et al (2004) Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20:441\u2013453","journal-title":"Immunity"},{"key":"424_CR92","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.4049\/jimmunol.0902551","volume":"184","author":"M Yang","year":"2010","unstructured":"Yang M, Sun L, Wang S, Ko KH, Xu H et al (2010) Cutting edge: novel function of B cell-activating factor in the induction of IL-10 producing regulatory B cells. J Immunol 184:3321\u20133325","journal-title":"J Immunol"},{"key":"424_CR93","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrn3468","volume":"14","author":"MC Papadopoulos","year":"2013","unstructured":"Papadopoulos MC, Verkman AS (2013) Aquaporin water channels in the nervous system. Nat Rev Neurosci 14:265\u2013277","journal-title":"Nat Rev Neurosci"},{"key":"424_CR94","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","volume":"71","author":"L Tradtrantip","year":"2012","unstructured":"Tradtrantip L, Zhang H, Saadoun S, Phuan P-W, Lam C et al (2012) Anti\u2013Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 71:314\u2013322","journal-title":"Ann Neurol"},{"key":"424_CR95","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1096\/fj.11-201608","volume":"26","author":"L Tradtrantip","year":"2012","unstructured":"Tradtrantip L, Zhang H, Anderson MO, Saadoun S, Phuan PW et al (2012) Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J 26:2197\u20132208","journal-title":"FASEB J"},{"key":"424_CR96","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1744-9987.1998.tb00102.x","volume":"2","author":"M Yoshida","year":"1998","unstructured":"Yoshida M, Tamura Y, Yamada Y, Yamawaki N, Yamashita Y (1998) Immusorba TR and Immusorba PH: basics of design and features of functions. Ther Apher 2:185\u2013192","journal-title":"Ther Apher"},{"key":"424_CR97","author":"L Elsone","year":"2013","unstructured":"Elsone L, Panicker J, Mutch K, Boggild M, Appleton R et al (2013) Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler J. doi: 10.1177\/1352458513495938","journal-title":"Mult Scler J"},{"key":"424_CR98","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jneuroim.2012.09.002","volume":"254","author":"H Kuroda","year":"2013","unstructured":"Kuroda H, Fujihara K, Takano R, Takai Y, Takahashi T et al (2013) Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. J Neuroimmunol 254:178\u2013182","journal-title":"J Neuroimmunol"},{"key":"424_CR99","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG et al (2013) Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 12:554\u2013562","journal-title":"Lancet Neurol"},{"key":"424_CR100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1742-2094-9-209","volume":"9","author":"M Benkhoucha","year":"2012","unstructured":"Benkhoucha M, Molnarfi N, Santiago-Raber ML, Weber MS, Merkler D et al (2012) IgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitis. J Neuroinflammation 9:209","journal-title":"J Neuroinflammation"},{"key":"424_CR101","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1182\/blood-2009-07-230631","volume":"115","author":"K Maeda","year":"2010","unstructured":"Maeda K, Mehta H, Drevets DA, Coggeshall KM (2010) IL-6 increases B-cell IgG production in a feed-forward proinflammatory mechanism to skew hematopoiesis and elevate myeloid production. Blood 115:4699\u20134706","journal-title":"Blood"},{"key":"424_CR102","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","volume":"108","author":"N Chihara","year":"2011","unstructured":"Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S et al (2011) Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 108:3701\u20133706","journal-title":"Proc Natl Acad Sci USA"},{"key":"424_CR103","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/00207450903428970","volume":"120","author":"S Icoz","year":"2010","unstructured":"Icoz S, Tuzun E, Kurtuncu M, Durmus H, Mutlu M et al (2010) Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int J Neurosci 120:71\u201375","journal-title":"Int J Neurosci"},{"key":"424_CR104","doi-asserted-by":"crossref","unstructured":"Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, et al. (2012). Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 1\u20135. doi: 10.1007\/s10165-012-0715-9","DOI":"10.1007\/s10165-012-0715-9"},{"key":"424_CR105","doi-asserted-by":"crossref","unstructured":"Kieseier BC, St\u00fcve O, Dehmel T, Goebels N, Leussink VI, et al. (2012). Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. Arch Neurol 1\u20134. doi: 10.1001\/jamaneurol.2013.668","DOI":"10.1001\/jamaneurol.2013.668"},{"key":"424_CR106","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","volume":"70","author":"I Ayzenberg","year":"2013","unstructured":"Ayzenberg I, Kleiter I, Schroder A, Hellwig K, Chan A et al (2013) Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 70:394\u2013397","journal-title":"JAMA Neurol"},{"key":"424_CR107","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","volume":"5","author":"M Mihara","year":"2005","unstructured":"Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S et al (2005) Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 5:1731\u20131740","journal-title":"Int Immunopharmacol"},{"key":"424_CR108","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","volume":"1813","author":"J Scheller","year":"2011","unstructured":"Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S (2011) The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimic et Biophys Acta (BBA) - Mol Cell Res 1813:878\u2013888","journal-title":"Biochimic et Biophys Acta (BBA) - Mol Cell Res"},{"key":"424_CR109","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1038\/cddis.2013.126","volume":"4","author":"M Leibinger","year":"2013","unstructured":"Leibinger M, Muller A, Gobrecht P, Diekmann H, Andreadaki A et al (2013) Interleukin-6 contributes to CNS axon regeneration upon inflammatory stimulation. Cell Death Dis 4:e609","journal-title":"Cell Death Dis"},{"key":"424_CR110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.expneurol.2012.03.019","volume":"236","author":"P Yang","year":"2012","unstructured":"Yang P, Wen H, Ou S, Cui J, Fan D (2012) IL-6 promotes regeneration and functional recovery after cortical spinal tract injury by reactivating intrinsic growth program of neurons and enhancing synapse formation. Exp Neurol 236:19\u201327","journal-title":"Exp Neurol"},{"key":"424_CR111","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/jnr.1108","volume":"64","author":"S Haggiag","year":"2001","unstructured":"Haggiag S, Zhang PL, Slutzky G, Shinder V, Kumar A et al (2001) Stimulation of myelin gene expression in vitro and of sciatic nerve remyelination by interleukin-6 receptor-interleukin-6 chimera. J Neurosci Res 64:564\u2013574","journal-title":"J Neurosci Res"},{"key":"424_CR112","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1006\/mcne.2002.1208","volume":"21","author":"A Valerio","year":"2002","unstructured":"Valerio A, Ferrario M, Dreano M, Garotta G, Spano P et al (2002) Soluble interleukin-6 (IL-6) receptor\/IL-6 fusion protein enhances in vitro differentiation of purified rat oligodendroglial lineage cells. Mol Cell Neurosci 21:602\u2013615","journal-title":"Mol Cell Neurosci"},{"key":"424_CR113","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.mcn.2005.10.014","volume":"31","author":"PL Zhang","year":"2006","unstructured":"Zhang PL, Izrael M, Ainbinder E, Ben-Simchon L, Chebath J et al (2006) Increased myelinating capacity of embryonic stem cell derived oligodendrocyte precursors after treatment by interleukin-6\/soluble interleukin-6 receptor fusion protein. Mol Cell Neurosci 31:387\u2013398","journal-title":"Mol Cell Neurosci"},{"key":"424_CR114","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.mcn.2003.10.022","volume":"25","author":"M Pizzi","year":"2004","unstructured":"Pizzi M, Sarnico I, Boroni F, Benarese M, Dreano M et al (2004) Prevention of neuron and oligodendrocyte degeneration by interleukin-6 (IL-6) and IL-6 receptor\/IL-6 fusion protein in organotypic hippocampal slices. Mol Cell Neurosci 25:301\u2013311","journal-title":"Mol Cell Neurosci"},{"key":"424_CR115","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ana.23741","volume":"73","author":"L Tradtrantip","year":"2013","unstructured":"Tradtrantip L, Ratelade J, Zhang H, Verkman AS (2013) Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol 73:77\u201385","journal-title":"Ann Neurol"},{"key":"424_CR116","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1158\/1078-0432.CCR-09-1483","volume":"15","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P et al (2009) A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res 15:7144\u20137152","journal-title":"Clin Cancer Res"},{"key":"424_CR117","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","volume":"6","author":"S Jarius","year":"2010","unstructured":"Jarius S, Wildemann B (2010) AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 6:383\u2013392","journal-title":"Nat Rev Neurol"},{"key":"424_CR118","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jns.2010.01.002","volume":"291","author":"S Jarius","year":"2010","unstructured":"Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B et al (2010) Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 291:52\u201356","journal-title":"J Neurol Sci"},{"key":"424_CR119","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/jnnp.2007.133330","volume":"79","author":"S Jarius","year":"2008","unstructured":"Jarius S, Franciotta D, Bergamaschi R, Rauer S, Wandinger KP et al (2008) Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 79:1134\u20131136","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"424_CR120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2013.05.010","volume":"262","author":"R Pedotti","year":"2013","unstructured":"Pedotti R, Musio S, Scabeni S, Farina C, Poliani PL et al (2013) Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption. J Neuroimmunol 262:19\u201326","journal-title":"J Neuroimmunol"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-014-0424-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00281-014-0424-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-014-0424-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T04:48:28Z","timestamp":1689223708000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00281-014-0424-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":120,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["424"],"URL":"https:\/\/doi.org\/10.1007\/s00281-014-0424-x","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}